Metropolitan Life Insurance CO Verve Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$10.81 - $17.96 $3,513 - $5,837	325 Added 10.15%	3,526 $46,000
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $4,602 - $8,390	403 Added 14.4%	3,201 $42,000
Q3 2022 Mar 30, 2023	BUY	$15.63 - $41.49 $5,392 - $14,314	345 Added 14.06%	2,798 $96,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $5,392 - $14,314	345 Added 14.06%	2,798 $96,000
Q2 2022 Jun 20, 2023	SELL	$11.14 - $23.17 $3,843 - $7,993	-345 Reduced 12.33%	2,453 $37,000
Q1 2022 Jun 20, 2023	SELL	$20.92 - $39.36 $7,217 - $13,579	-345 Reduced 12.33%	2,453 $55,000
Q1 2022 Mar 30, 2023	SELL	$20.92 - $39.36 $40,710 - $76,594	-1,946 Reduced 44.24%	2,453 $55,000
Q1 2022 May 12, 2022	SELL	$20.92 - $39.36 $40,710 - $76,594	-1,946 Reduced 44.24%	2,453 $56,000
Q4 2021 Jun 21, 2023	BUY	$31.94 - $54.82 $51,135 - $87,766	1,601 Added 57.22%	4,399 $162,000
Q3 2021 Jun 21, 2023	BUY	$46.0 - $73.99 $73,646 - $118,457	1,601 Added 57.22%	4,399 $206,000
Q3 2021 Mar 30, 2023	BUY	$46.0 - $73.99 $73,646 - $118,457	1,601 Added 57.22%	4,399 $206,000
Q3 2021 Nov 15, 2021	BUY	$46.0 - $73.99 $202,354 - $325,482	4,399 New	4,399 $207,000

181

73.4M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $489M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.